Oral Androgens in Man-4: (Short Title: Oral T-4) - Full Text View

Sponsor:	University of Washington
Collaborator:	GlaxoSmithKline
Information provided by:	University of Washington
ClinicalTrials.gov Identifier:	NCT00399165

Purpose

The protocol was designed to address the hypothesis that oral testosterone enanthate plus dutasteride can suppress the secretion of LH and FSH after four weeks of administration. In addition, we will compare the gonadotropin suppression mediated by a dose of testosterone enanthate (400 mg twice daily) that would be expected to maintain the serum testosterone in the normal range throughout the day, with the same dose (800 mg once daily) administered once daily. This larger once-daily dose is expected to result in a higher peak and lower trough by the end of the dosing interval

Condition	Intervention	Phase
Contraception	Drug: Testosterone Enanthate Drug: Dutasteride Other: placebo sesame oil	Phase I Phase II

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment
Official Title:	Oral Androgens in Man-4: Gonadotropin Suppression Medicated by Oral Testosterone Enanthate in Oil Plus Dutasteride (Short Title: Oral T-4)

Resource links provided by NLM:

MedlinePlus related topics: Birth Control

Drug Information available for: Testosterone Propionate Methyltestosterone Testosterone Dutasteride Oxymesterone Testosterone enanthate Testosterone undecanoate Sesame oil

U.S. FDA Resources

Further study details as provided by University of Washington:

Primary Outcome Measures:

Dutasteride can suppress the secretion of LH and FSH after four weeks of administration. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

The ability of oral testosterone enanthate plus dutasteride to maintain short-term androgen-medicated endpoints such as mood and sexual function over the 4-week treatment period [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Enrollment:	20
Study Start Date:	November 2006
Study Completion Date:	May 2007
Primary Completion Date:	May 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: 1 Oral Testosterone enanthate in sesame oil, 400 mg po (orally), BID (twice daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once	Drug: Testosterone Enanthate Oral Testosterone 400 mg orally for 28 days Other Name: Delatestryl Drug: Dutasteride dutasteride 0.5 mg orally, once daily for 28 days Other Name: Avodart Drug: Dutasteride 24.5 mg po once (Day 0) Other Name: Avodart
Active Comparator: 2 Oral Testosterone sesame oil, 800 mg po (orally), qd (in am daily) + placebo sesame oil (in pm daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once	Drug: Testosterone Enanthate Oral Testosterone 800 mg orally for 28 days Other Name: Delatestryl Drug: Dutasteride dutasteride 0.5 mg orally, once daily for 28 days Other Name: Avodart Other: placebo sesame oil placebo sesame oil Drug: Dutasteride 24.5 mg po once (Day 0) Other Name: Avodart

Detailed Description:

This study will be carried out in a double-blinded fashion, so neither the subject nor the investigator will be aware of treatment assignment during the study. This protocol is designed to address the hypothesis that oral testosterone enanthate plus dutasteride can suppress the secretion of LH and FSH after four weeks of administration. In addition, we will compare the gonadotropin suppression mediated by a dose of testosterone enanthate (400 mg twice daily) that would be expected to maintain the serum testosterone in the normal range throughout the day, with the same dose (800 mg once daily) administered once daily. This larger once-daily dose is expected to result in a higher peak and lower trough by the end of the dosing interval. Secondary endpoints in this study include the ability of oral testosterone enanthate plus dutasteride to maintain short-term androgen-mediated endpoints such as mood and sexual function over the 4-week treatment period as well as weekly measures of safety, including blood counts, PSA and liver and kidney function.

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Males between 18 to 55 years of age
In good general health based on normal screening evaluation (consisting of a medical history, physical exam, normal serum chemistry, hematology, and baseline hormone levels)
Subject must agree not to participate in another research drug study for the duration of the study
Subject must agree to not donate blood during the study
Subject must be willing to comply with the study protocol and procedures

Exclusion Criteria:

Men in poor general health, with abnormal blood results (clinical laboratory tests or hormone values)
A known history of alcohol or drug abuse
A history of testicular disease or severe testicular trauma,
A history of bleeding disorders or current use of anti-coagulants
A history of sleep apnea and/or major psychiatric disorders
A body-mass index greater than 35,
A history of or current use of testosterone
Infertility

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00399165

Locations

United States, Washington
University of Washington
Seattle, Washington, United States, 98195

Sponsors and Collaborators

University of Washington

GlaxoSmithKline

Investigators

Principal Investigator:

John K Amory, MD, MPH

University of Washington

More Information

Additional Information:

University of Washington This link exits the ClinicalTrials.gov site

Publications:

Amory JK, Kalhorn TF, Page ST. Pharmacokinetics and Pharmacodynamics of Oral Testosterone Enanthate Plus Dutasteride for Four Weeks in Normal Men: Implications for Male Hormonal Contraception. J Androl. 2007 Nov 28; [Epub ahead of print]

Martin CW, Anderson RA, Cheng L, Ho PC, van der Spuy Z, Smith KB, Glasier AF, Everington D, Baird DT. Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod. 2000 Mar;15(3):637-45.

Weston GC, Schlipalius ML, Bhuinneain MN, Vollenhoven BJ. Will Australian men use male hormonal contraception? A survey of a postpartum population. Med J Aust. 2002 Mar 4;176(5):208-10.

Heinemann K, Saad F, Wiesemes M, White S, Heinemann L. Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod. 2005 Feb;20(2):549-56. Epub 2004 Dec 17.

Amory JK, Bremner WJ. Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. J Clin Endocrinol Metab. 2005 May;90(5):2610-7. Epub 2005 Feb 15.

Amory JK, Page ST, Bremner WJ. Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. J Androl. 2006 Jan-Feb;27(1):72-8.

Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab. 1996 Feb;81(2):757-62.

Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl. 1999 May-Jun;20(3):407-14.

Anawalt BD, Amory JK, Herbst KL, Coviello AD, Page ST, Bremner WJ, Matsumoto AM. Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial. J Androl. 2005 May-Jun;26(3):405-13.

Responsible Party:	John K Amory, MD, MPH, University of Washington
ClinicalTrials.gov Identifier:	NCT00399165 History of Changes
Other Study ID Numbers:	06-2962-A, U54 HD42454, K23 HD045386
Study First Received:	November 9, 2006
Last Updated:	September 18, 2008
Health Authority:	United States: Food and Drug Administration

Keywords provided by University of Washington:

Oral Contraception for Men
Contraceptive agent

Additional relevant MeSH terms:

Testosterone
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Androgens
Methyltestosterone
Contraceptive Agents
Dutasteride
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists

Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses
Anabolic Agents
Reproductive Control Agents
5-alpha Reductase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on February 09, 2012